Pre-made Sifalimumab benchmark antibody ( Whole mAb, anti-IFNA1 therapeutic antibody, Anti-IFL/IFN3/leIF DD Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-519

Pre-Made Sifalimumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-519-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Sifalimumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody
INN Name Sifalimumab
TargetIFNA1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure4ypg:HL:BA
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesMedarex;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMyositis;Psoriasis;Systemic lupus erythematosus
Development Techna